The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Large Will The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Be By 2030 Compared To Its 2026 Market Size?
The market size for nucleic acid and gene therapies in neuromuscular disorders has demonstrated substantial growth in recent years. This market is projected to expand from $7.5 billion in 2025 to $8.22 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.7%. The historical increase in this sector can be attributed to factors like the limited therapeutic options available for nmds, low awareness concerning gene therapies, the high costs involved in gene therapy development, a scarcity of specialized treatment centers, and slow regulatory approval procedures.
The nucleic acid and gene therapies in neuromuscular disorders market size is projected to experience substantial growth in the coming years. It is forecast to grow to $11.76 billion by 2030, expanding at a compound annual growth rate (CAGR) of 9.4%. The anticipated growth over this period is attributable to advancements in adeno-associated virus and postnatal gene therapies, a surge in research and development investments in neuromuscular disorders, an increasing number of hospitals and specialty clinics offering gene therapies, the rising prevalence of neuromuscular disorders, and heightened patient awareness and advocacy initiatives. Key trends during the forecast period involve a growing embrace of gene therapy techniques, expanded development of nucleic acid therapeutics, an amplified focus on rare neuromuscular disorders, increased investment in personalized medicine approaches, and greater integration of advanced diagnostic and monitoring tools.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21233&type=smp
What Primary Drivers Are Shaping The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market?
A growing incidence of genetic disorders is projected to boost the expansion of the nucleic acid and gene therapies in neuromuscular disorders market in the future. These disorders are conditions resulting from anomalies in an individual’s DNA, which can either be inherited or acquired through mutations. The rise in genetic disorders stems from factors such as genetic mutations, environmental impacts, lifestyle modifications, and enhanced diagnostic capabilities. Nucleic acid and gene therapies offer assistance for genetic disorders by correcting or replacing faulty genes in neuromuscular conditions, aiming to restore normal physiological function. For example, in May 2024, data from Cure SMA, a US-based non-profit organization, indicated that approximately 9,000 to 9,500 individuals in the United States are currently living with Spinal Muscular Atrophy (SMA). Among this total population, 37% have Type 2 SMA, and the condition has an estimated incidence rate of 1 in 15,000 births. Thus, the increasing prevalence of genetic disorders is a key driver for the growth of the nucleic acid and gene therapies in neuromuscular disorders market.
How Are Different Segments Classified In The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Segment Analysis?
The nucleic acid and gene therapies in neuromuscular disorders market covered in this report is segmented –
1) By Disorder: Motor Neuron Diseases, Neuropathies, Neuromuscular Junction Disorders, Myopathies Including Muscular Dystrophies
2) By Therapy: Adeno-Associated Viruses Gene Therapy, Postnatal Gene Therapy
3) By End-User: Hospitals, Specialty Clinics, Ambulatory Surgery Centers
Subsegments:
1) By Motor Neuron Diseases: Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA), Primary Lateral Sclerosis (PLS)
2) By Neuropathies: Charcot-Marie-Tooth Disease (CMT), Hereditary Sensory and Autonomic Neuropathy (HSAN), Peripheral Neuropathies
3) By Neuromuscular Junction Disorders: Myasthenia Gravis, Lambert-Eaton Myasthenic Syndrome (LEMS)
4) By Myopathies Including Muscular Dystrophies: Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD), Limb-Girdle Muscular Dystrophy (LGMD), Facioscapulohumeral Muscular Dystrophy (FSHD)
What Trends Are Affecting The Growth Of The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market?
Within the nucleic acid and gene therapies in neuromuscular disorders market, major companies are actively developing innovative treatments, such as gene therapy, to target the fundamental causes of genetic neuromuscular conditions through precise gene correction or replacement. Gene therapy involves the medical intervention of introducing, altering, or repairing genetic material within a patient’s cells to correct or replace defective genes. For example, in June 2023, Sarepta Therapeutics Inc., a US-based biotechnology company, secured approval from the U.S. Food and Drug Administration for Elevidys, the inaugural gene therapy for Duchenne Muscular Dystrophy, specifically for ambulatory pediatric patients aged 4 to 5 years. This therapy is administered as a single intravenous infusion, simplifying the treatment process compared to other therapies that might require continuous infusions. ELEVIDYS delivers a gene that codes for a shortened form of dystrophin known as micro-dystrophin, which is crucial for muscle function. This pioneering method addresses the underlying genetic defect by enabling muscle cells to produce a functional version of the dystrophin protein, potentially halting or reversing the progression of the disease.
Who Are The Companies Driving Activity In The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market?
Major companies operating in the nucleic acid and gene therapies in neuromuscular disorders market are Pfizer Inc, F. Hoffmann-La Roche Ltd, Sanofi S.A, Novartis AG, Biogen Inc, BioMarin Pharmaceuticals Inc, Sarepta Therapeutics Inc, Ionis Pharmaceuticals Inc, Ultragenyx Pharmaceutical Inc, Regenxbio Inc, UniQure N.V, Généthon S.A, Axovant Gene Therapies Inc, PTC Therapeutics Inc, Wave Life Sciences Ltd, CRISPR Therapeutics AG, Editas Medicine Inc, Helixmith Co Ltd, MeiraGTx Ltd, Cure Rare Disease, Beam Therapeutics Inc, Intellia Therapeutics Inc, Prime Medicine Inc, Arcturus Therapeutics Holdings Inc, Takeda Pharmaceutical Company Ltd.
Get The Full Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Report:
Which Region Leads The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market In Terms Of Market Share?
North America was the largest region in the nucleic acid and gene therapies in neuromuscular disorders market in 2025. The regions covered in the nucleic acid and gene therapies in neuromuscular disorders market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market 2026, By The Business Research Company
Prostate Cancer Nuclear Medicine Diagnostics Market Report 2026
Nuclear Medicine Market Report
https://www.thebusinessresearchcompany.com/report/nuclear-medicine-global-market-report
Hereditary Cancer Testing Market Report
https://www.thebusinessresearchcompany.com/report/hereditary-cancer-testing-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model